Oscar Health (NYSE:OSCR) Upgraded at Zacks Research

Oscar Health (NYSE:OSCR) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other brokerages have also weighed in on OSCR. Weiss Ratings restated a “sell (d)” rating on shares of Oscar Health in a research report on Tuesday, April 21st. Raymond James Financial upgraded shares of Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a research report on Thursday, February 12th. Wolfe Research began coverage on shares of Oscar Health in a research report on Tuesday. They issued a “peer perform” rating on the stock. Robert W. Baird raised their target price on shares of Oscar Health from $15.00 to $19.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, Wall Street Zen upgraded shares of Oscar Health from a “hold” rating to a “strong-buy” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Oscar Health currently has a consensus rating of “Hold” and a consensus price target of $18.22.

Oscar Health Stock Performance

NYSE:OSCR opened at $21.28 on Thursday. The stock’s 50-day simple moving average is $14.43 and its 200 day simple moving average is $15.29. The firm has a market capitalization of $6.34 billion, a PE ratio of -36.07, a price-to-earnings-growth ratio of 2.78 and a beta of 2.34. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 0.44. Oscar Health has a twelve month low of $10.69 and a twelve month high of $23.80.

Oscar Health (NYSE:OSCR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.96. Oscar Health had a negative return on equity of 3.73% and a negative net margin of 0.30%.The business had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.90 billion. During the same period last year, the firm posted $0.92 earnings per share. Oscar Health’s revenue was up 52.6% compared to the same quarter last year. On average, analysts anticipate that Oscar Health will post 0.25 EPS for the current fiscal year.

Insider Activity at Oscar Health

In other Oscar Health news, CEO Mark T. Bertolini purchased 1,000,000 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were bought at an average price of $11.92 per share, for a total transaction of $11,920,000.00. Following the completion of the acquisition, the chief executive officer owned 10,196,876 shares in the company, valued at approximately $121,546,761.92. This trade represents a 10.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 24.39% of the company’s stock.

Hedge Funds Weigh In On Oscar Health

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Oscar Health by 2.7% during the fourth quarter. Vanguard Group Inc. now owns 20,701,250 shares of the company’s stock worth $297,477,000 after purchasing an additional 540,851 shares during the period. T. Rowe Price Investment Management Inc. lifted its stake in shares of Oscar Health by 11.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company’s stock worth $132,461,000 after acquiring an additional 910,320 shares during the period. Morgan Stanley lifted its stake in shares of Oscar Health by 42.8% in the fourth quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock worth $97,918,000 after acquiring an additional 2,043,758 shares during the period. Thrive Capital Management LLC lifted its stake in shares of Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after acquiring an additional 1,588,395 shares during the period. Finally, BIT Capital GmbH lifted its stake in shares of Oscar Health by 545.0% in the fourth quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock worth $88,897,000 after acquiring an additional 5,227,152 shares during the period. Institutional investors and hedge funds own 75.70% of the company’s stock.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.